Back to results
US 2022/0089741 A1Published application
Binder against programmed death-ligand and application thereof
AssigneeHuabo Biopharm (Shanghai) Co., Ltd.
InventorsHaijia YU, Ling YU, Mingqing CAI, Xiangyang ZHU
Life of this patent
Estimating the term…
Abstract
Provided is an anti-PD-L1 monoclonal antibody. The antibody can be used to prepare a drug for preventing or treating a disease related to PD-L1.
Claims13
A heavy chain variable region of an antibody, wherein the heavy chain variable region comprises the following three complementarity determining regions or CDRs:
- CDR1 as shown in SEQ ID NO:
- 3,
- CDR2 as shown in SEQ ID NO:
- 4, and
- CDR3 as shown in SEQ ID NO:
- 5.
3 more elements
3-4. (canceled)
(canceled)
Dependencies are inferred from the claim text.